3 Stocks That Soared Stupendously This Week презентация

double-digit gains. Few performed as nicely as these three big winners, though.

1

2

3

for the week.

PTC Therapeutics (Nasdaq:PTCT)

Source: Yahoo! Finance

positive opinion for PTC’s translarna
Translarna targets treatment of rare disease nonsense mutation Duchenne muscular dystrophy, or nmDMD
PTC still must await a final decision by the European Medicines Agency, which is expected in a few months

Why PTC shot up PDQ

(Nasdaq:RNA)

Source: Yahoo! Finance

PTC Therapeutics’ shares on PTC’s good news in Europe
Prosensa is also hoping to win European approval for its Duchenne Muscular Dystrophy (DMD) drug, drisapersen
The other big player in the DMD arena, Sarepta Therapeutics (Nasdaq:SRPT), also received a nice 8% bump for the week
Sarepta’s shares, however, have already surged a lot since mid-April and didn’t get quite the jolt felt by Prosensa and PTC

Why Prosensa shares popped

vaulted 22% higher this week.

Ophthotech Corp (Nasdaq:OPHT)

Source: Yahoo! Finance

treatment of patients newly diagnosed with wet AMD, a chronic eye disease
Novartis gains marketing rights for Fovista outside of the U.S. with Ophthotech keeping U.S. rights
The deal could be worth $1 billion to Ophotech over time

Why Ophthotech shares took off

going
PTC Therapeutics looks to have a great shot at obtaining European approval for translarna
Prosensa also seems to have a good chance at getting a positive decision across the Atlantic for drisapersen
Novartis’ endorsement of Fovista – accompanied by a nice $200 million upfront payment – bodes well for Ophotech
While any of these stocks could experience a pullback after this week’s big gains, all could be winners over the long run

Best pick to keep soaring?

?

as the top pick for 2014 in our free report!